EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

VEXAS syndrome: is it more a matter of inflammation or hematopoietic clonality? A case series approach to diagnosis, therapeutic strategies and transplant management

Alessandro Costa, Federica Pilo, Martina Pettinau, Matteo Piga, Pietro Carboni, Eugenia Piras, Clara Targhetta, Rodrigo Rojas, Paola Deias, Olga Mulas, Giovanni Caocci

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06207-2 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of Hematology, 2025. Verfasst von Alessandro Costa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, 09121, Italy. alessandrocosta161195@gmail.com. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Myelodysplastic Syndromes, Clonal Hematopoiesis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Cagliari.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

VEXAS syndrome is a complex hemato-inflammatory disorder, driven by somatic mutations in the UBA1 gene within hematopoietic precursor cells. It is characterized by systemic inflammation, rheumatological manifestations, and frequent association with myelodysplastic syndrome (MDS). We present a series of four VEXAS cases, all of which include concomitant MDS, each displaying distinct genetic signatures and clinical features at diagnosis, with a focus on their diagnostic and therapeutic implications. Our findings underscore the importance of extending UBA1 sequencing beyond exon 3 in cases with strong clinical suspicion. Given the rarity of non-canonical variants and the limited gene annotation, germline tissue control should be considered to differentiate somatic from germline mutations. Hematological management, including considerations for transplantation, was primarily guided by the Revised International Prognostic Scoring System (IPSS-R) for MDS due to the absence of a specific risk stratification system for VEXAS or therapy guidelines. A critical point of our discussion is the role of inflammation in the peri-transplant period; in one patient, the combination of disease-modifying antirheumatic drugs (DMARDs) and high-dose corticosteroids before transplant was crucial in controlling inflammation, resulting in a successful hematopoietic stem cell transplantation (HSCT). In contrast, uncontrolled inflammation contributed to the peri-transplant death of another patient. These cases highlight the importance of effective inflammation management in optimizing HSCT outcomes. Additionally, our study emphasizes the urgent need for specific management guidelines for VEXAS syndrome, including a comprehensive risk stratification system and optimal timing for transplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationMyelodysplastic SyndromesClonal HematopoiesisHumansMaleMiddle AgedFemaleAdultInflammationUbiquitin-Activating EnzymesAgedDiabetes Mellitus, Type 1DiarrheaImmune System DiseasesGenetic Diseases, X-LinkedSkin Diseases, Genetic

Stichwörter der Autor:innen

Exon 14Hematopoietic cell transplantInflammationUBA1VEXAS syndrome

Substanzen

UBA1 protein, humanUbiquitin-Activating Enzymes

Autor:innen und Institutionen

  • Hematology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, 09121, Italy. alessandrocosta161195@gmail.com.
  • Hematology and BMT Unit, "A. Businco" Hospital, ARNAS Brotzu, Cagliari, Italy.
  • Rheumatology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, 09121, Italy.
  • UOC Reumatologia, Azienda Ospedaliero Universitaria Cagliari, Monserrato, CA, ss 554, 09032, Italy.
  • Hematology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, 09121, Italy.

Förderung

  • Università degli Studi di Cagliari

Zitieren

APA

Costa, A., Pilo, F., Pettinau, M., Piga, M., Carboni, P., Piras, E., Targhetta, C., Rojas, R., Deias, P., Mulas, O., & Caocci, G. (2025). VEXAS syndrome: is it more a matter of inflammation or hematopoietic clonality? A case series approach to diagnosis, therapeutic strategies and transplant management. Annals of Hematology. https://doi.org/10.1007/s00277-025-06207-2

Vancouver

Costa A, Pilo F, Pettinau M, Piga M, Carboni P, Piras E, et al. VEXAS syndrome: is it more a matter of inflammation or hematopoietic clonality? A case series approach to diagnosis, therapeutic strategies and transplant management. Annals of Hematology. 2025. doi:10.1007/s00277-025-06207-2

BibTeX
@article{Costa2025,
  author = {Costa, Alessandro and Pilo, Federica and Pettinau, Martina and Piga, Matteo and Carboni, Pietro and Piras, Eugenia and Targhetta, Clara and Rojas, Rodrigo and Deias, Paola and Mulas, Olga and Caocci, Giovanni},
  title = {VEXAS syndrome: is it more a matter of inflammation or hematopoietic clonality? A case series approach to diagnosis, therapeutic strategies and transplant management},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06207-2}
}
Kostenlos starten →